Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 9/20 | 0.40 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.39 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | RAF1 | P04049 | 2/20 | 0.39 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.39 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.39 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.39 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 3/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.37 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.37 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12227091 | 0.93 | BRAF (0.39) | BRAFHSD17B1HSD17B2MAPK14RAF1 | |
| SCHEMBL2479421 | 0.74 | FYN (0.41) | BRAFHSD17B1HSD17B2MAPK14RAF1 | |
| SCHEMBL2478416 | 0.72 | FYN (0.40) | BRAFHSD17B1HSD17B2MAPK14RAF1 | |
| SCHEMBL2478432 | 0.69 | TP53 (0.46) | BRAFHSD17B1HSD17B2 | |
| SCHEMBL2481024 | 0.68 | LMNA (0.48) | BRAFMAPK14 | |
| SCHEMBL2477533 | 0.65 | FYN (0.42) | BRAFHSD17B1HSD17B2MAPK14RAF1 | |
| SCHEMBL1138550 | 0.65 | CYP17A1 (0.70) | BRAFHSD17B1HSD17B2MAPK14RAF1 | |
| SCHEMBL3656450 | 0.62 | BRAF (0.51) | BRAFMAPK14RAF1MAPK13MAPK12 | |
| SCHEMBL2480280 | 0.61 | KMO (0.40) | MAPK14FYNCSNK2A2CSNK2B | |
| SCHEMBL14414441 | 0.58 | RAF1 (0.53) | BRAFHSD17B1HSD17B2MAPK14RAF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | claimed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | claimed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | claimed |
| EP-2373664-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | claimed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | claimed |
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| US-8524707-B2 | Bicyclic pyrazoles as protein kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2013-09-03 | — | — | US | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| EP-2373664-B1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2013-06-12 | — | — | EP | disclosed |
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-10-20 | — | — | US | disclosed |
| EP-2373664-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | Nerviano Medical Sciences S.r.l. (IT) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010070060-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257165-A1 | BICYCLIC PYRAZOLES AS PROTEIN KINASE INHIBITORS | MAP3K19, MAP4K3, MAP3K15 | BRAF 41/4885HSD17B1 2572/4885HSD17B2 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.